Mediocre performance in the first quarter, Roche is still expected to achieve annual target
Recently, Roche announced its first quarter results. 2011 3 months, Group sales in local currency stable at 11.1 billion Swiss francs, down 9% over the previous year. Pharmaceuticals Division continued to show slow growth, such as the total Ruda Fei, if the total Ruda Fei, coupled with the expected adverse effects, sales decreased 2%.
The Diagnostics Division maintained its strong performance, sales growth continues to outpace the global in vitro diagnostics market level, in local currency increased by 6% to 2.4 billion Swiss francs.
Performance for the first quarter, Roche Group identified the target year. The Group and Pharmaceuticals Division (excluding Tamiflu) will be expected to lower the rate of growth in the number of units, of which the growth rate of the Pharmaceuticals Division consistent with the market average, while the Diagnostics Division is far more than the market growth rate will be higher digit growth rate.
Evaluation Group, when the first quarter of 2011, Roche CEO Schwann said: "Our first quarter sales, we expected to achieve annual goals. Since the beginning of this year, we have announced seven key Ⅱ or Ⅲ clinical positive test results, and thus further promote the development of our future in the coming years. "
Involvement of Tamiflu, the slow growth of the pharmaceutical sector
Roche in the first quarter total sales to 87 billion Swiss francs, down by 2% in local currency. This is also related with the poor performance of Tamiflu. According to statistics, sales of Tamiflu fell sharply compared with last year, the overall antiviral drugs Tamiflu sales continue to decline, dropping to 47%, from CHF 517 million down to 252 million Swiss francs, which is expected consistent. Excluding Ruda Fei, the Pharmaceuticals Division sales increased by 1%. Roche is expected to achieve the annual target.
Early last year, compared with U.S. sales in the first quarter of 2011 increased 2%, Western Europe and Japan were down 4%, 7%. These areas reflect sales since the first quarter of 2010 the high base effect and the U.S. health care reform, austerity measures in Europe, Japan, the continuing impact of reduced reimbursement prices, but there has been a national increase in sales of the Tamiflu.
In addition to Japan, the decline in performance down drug prices, but also with a large earthquake. Since March 11 devastating earthquake and tsunami in Japan since the Japanese subsidiary of Roche - Chugai Pharmaceutical Co., Ltd. is located in Utsunomiya factory has stopped production for damage assessment and repair. Some production has been restarted, the majority of Chinese and foreign business is expected to recover in the third quarter. Bio-active ingredient production facilities are not being destroyed. So far, foreign recovery plan has been developed and continue to supply products for the local market.
In addition, due to the impact of patent expiration, is not optimistic about the prospects for individual drugs. NeoRecormon and Chugai Roche's Epogin (erythropoietin β) of the total sales declined 22% to 246 million Swiss francs. Following the mid-patent in 2009, the end of 2010 in the U.S., Western Europe after the expiration of MMF sales dropped 14% to 280 million Swiss francs.
Positive full-year results of clinical results
In the first quarter, Roche announced the seven positive results of pivotal clinical trials, 6 of which are expected to promote the new drug application or marketing of new indications for existing products. Vemurafenib approved for use in metastatic melanoma, vismodegib approved for use in basal cell carcinoma, Tarceva approved for use in EGFR mutation - positive non-small cell lung cancer, Lucentis approved for diabetic macular edema, Trastuzumab emtansine approved in T-DM1, and HER2-positive metastatic breast cancer.
If included in other recent studies, since last October, the Group of 18 Ⅱ or Ⅲ trial has achieved positive results. Roche and Genentech plans to submit the results of most tests used in 2011 at a medical conference on the release.
In good news, the particular results of an An Weiting not rise. An Weiting approved for use in ovarian cancer is also cause for concern, but as a potential "blockbuster", the drug's fate depends on the outcome of litigation FDAs.
First quarter sales of the drug fell by 6% to 1.4 billion Swiss francs. Because the United States and Western Europe dropped completely offset by sales of regional and international double-digit growth in Japan.
An Weiting the United States and Western Europe sales for the following factors adversely affected: indications for monitoring metastatic breast cancer and the uncertainty of reimbursement and the 2010 launch of the U.S. health care reform and austerity measures in Europe.
This year in February, the U.S. FDA approval in June 28,29 at the two-day hearing was held to enable Roche to have opportunity to explain why the FDA should continue nuclear 准将安维汀 for the treatment of metastatic breast cancer. Before the end of the FDA action, An Weiting being approved in the United States and chemotherapy for the treatment of metastatic breast cancer.